Detailseite
Projekt Druckansicht

Analyse der Rolle der B Zellen im sporadischen und Kolitis-assoziiertem Kolonkarzinom

Antragstellerin Dr. Nadine Hövelmeyer
Fachliche Zuordnung Immunologie
Förderung Förderung von 2018 bis 2022
Projektkennung Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 397675136
 
Erstellungsjahr 2023

Zusammenfassung der Projektergebnisse

Patients with inflammatory bowel diseases are at increased risk of developing colitisassociated colorectal cancer (CAC). Chronic inflammation is a hallmark of many cancers as it facilitates the development of neoplastic cells by creating a pro-tumoral milieu. By using B celldeficient mice (JHT-/-), we could demonstrate that B cells play a key role in the development of CAC in the AOM/DSS model, since JHT-/- mice were completely tumour-resistant. Reconstitution of JHT-/- mice by an adoptive B cell-transfer of wildtype (WT) CD19+ splenocytes prior to AOM/DSS treatment restored tumour growth in these mice. Analysis of the inflammation phase (day 14) between WT and JHT-/- mice revealed that the absence of B cells results in decreased accumulation of immune cells, mainly pathogenic Th1 and Th17 cells, in the colonic lamina propria (LP) and reduced levels of pro-inflammatory cytokines, such as Il6, Il1ß, and Il17, hereby preventing the establishment of a proinflammatory milieu that promotes tumorigenesis. The more severe colitis in WT animals required increased regeneration of the intestinal epithelium, as evidenced by a higher number of proliferating (Ki67+) epithelial cells compared to JHT-/- animals. Exacerbated activation of proliferation both stimulates the repair of the epithelium but also the growth of AOM-induced mutagenic cells, which may explain the tumour resistance seen in the less-inflamed JHT-/- animals. We could not confirm a role of B cells as antibody-secreting cells in the development of CAC, although antibody levels were elevated in WT animals during inflammation as well as in tumorous tissue. Antibody-deficient IgMi mice showed the same tumour burden as WT mice. We wanted to find out whether B cells exert a regulatory function in CAC by secreting IL-10, similarly to IL-10 producing Treg cells, which are known to exert immunosuppressive and tumour promoting properties. Although mice lacking IL- 10 in B cells (IL-10BKO mice) display similar DSS-driven inflammation as control mice, tumour progression was significantly reduced compared to littermate controls, indicated by a reduced tumour number and tumour size. Analysis of tumorous tissue revealed that loss of B-cell-specific IL-10 largely prevented the activation of pro-tumoral M2-macrophages, as evidenced by markedly reduced expression of the M2-specific marker arginase 1 (Arg1) as well as the mannose receptor CD206. Thus, impaired M2-macrophage activation could impede CAC tumour progression in IL-10BKO mice. In conclusion, we demonstrated that B cells influence the severity of DSS inflammation in the AOM/DSS model and thus promote the initiation of CAC. Furthermore, our data indicate that IL-10-secreting B cells promote tumor progression. This indicates that there is not only one B-cell-associated mechanism leading to the development of CAC, but rather it is a combination of multiple factors.

Projektbezogene Publikationen (Auswahl)

 
 

Zusatzinformationen

Textvergrößerung und Kontrastanpassung